World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
45
Citations
7138
World Ranking
4714
National Ranking
2126

Overview

Jacquelyn A. Hank is affiliated with the University of Wisconsin-Madison in the United States. Their research primarily spans the fields of Medicine, Biochemistry, Genetics and Molecular Biology, and Immunology and Microbiology. Within these areas, they have contributed extensively to subfields including Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Neurology, and Molecular Biology.

The scientist's work addresses several main research topics, which include:

  • Immunotherapy and Immune Responses
  • Neuroblastoma Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Cancer therapeutics and mechanisms
  • Radiopharmaceutical Chemistry and Applications

Jacquelyn A. Hank has authored publications in multiple scientific journals and venues. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Clinical Cancer Research

Recent papers authored or co-authored by Jacquelyn A. Hank feature a focus on immunotherapy and neuroblastoma and include the following:

  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032, 2021, Clinical Cancer Research
  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group, 2020, Journal of Clinical Oncology
  • Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group, 2022, Journal of Clinical Oncology
  • Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice, 2021, Journal for ImmunoTherapy of Cancer
  • Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models, 2021, Frontiers in Immunology

Frequent collaborators in Jacquelyn A. Hank's research include:

  • Paul M. Sondel
  • Amy K. Erbe
  • Zachary S. Morris
  • Alexander L. Rakhmilevich
  • Arika S. Feils

Best Publications

  • NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

    Wei Wang;Amy K. Erbe;Jacquelyn A. Hank;Zachary S. Morris

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

    Jami D. Frost;Jami D. Frost;Jacquelyn A. Hank;Gregory H. Reaman;Sharon Frierdich

  • Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

    David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank

  • Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

    Andrew L. Gilman;M. Fevzi Ozkaynak;Katherine K. Matthay;Mark Krailo

  • Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

    Jacquelyn A. Hank;Randy R. Robinson;Jean Surfus;Barbara M. Mueller

  • Human T lymphocyte clones reactive in primed lymphocyte typing and cytotoxicity

    Fritz H. Bach;Hiroo Inouye;Jacquelyn A. Hank;Barbara J. Alter

  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

    Alice L. Yu;Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Arlene Naranjo

  • Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen

  • Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

    Jeff A. Sosman;Peter C. Kohler;Jacquelyn Hank;Karen H. Moore

  • Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

    Paul M. Sondel;Peter C. Kohler;Jacquelyn A. Hank;Karen H. Moore

  • A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

    Sara M. Federico;Sara M. Federico;M. Beth McCarville;Barry L. Shulkin;Paul M. Sondel

  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.

    Rajen Mody;Alice L Yu;Alice L Yu;Arlene Naranjo;Fan F Zhang

  • In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

    Zachary S. Morris;Emily I. Guy;David M. Francis;Monica M. Gressett

  • Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

    Fariba Navid;Paul M. Sondel;Raymond Barfield;Barry L. Shulkin

  • Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

    P M Sondel;J A Hank;P C Kohler;B P Chen

  • TCGF production for cloning and growth of functional human T lymphocytes.

    H. Inouye;J. A. Hank;B. J. Alter;F. H. Bach

  • Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

    Zane C. Neal;Jeannie C. Yang;Alexander L. Rakhmilevich;Ilia N. Buhtoiarov

  • Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.

    D M Mahvi;M B Henry;M R Albertini;S Weber

  • Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

    Jacquelyn A. Hank;Jean E. Surfus;Jacek Gan;Peter Jaeger

  • Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

    Jeff A. Sosman;Peter C. Kohler;Jacquelyn A. Hank;Karen H. Moore

  • Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

    Jean E. Surfus;Jacquelyn A. Hank;Egbert Oosterwijk;Sydney Welt

Frequent Co-Authors

Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Stephen D. Gillies
Stephen D. Gillies MSD (United States)
Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Alice L. Yu
Alice L. Yu University of California, San Diego
Wendy B. London
Wendy B. London Harvard University
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Joan H. Schiller
Joan H. Schiller University of Virginia
Alan J. Korman
Alan J. Korman VIR Biotechnology (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can expand career options. Nursing professions, in particular, often intersect with immunological knowledge. If you're starting your nursing journey, consider programs that are accessible and efficient. For example, the fastest and easiest LPN programs provide a quick pathway into practical nursing roles, laying a strong foundation for advanced studies.

As you advance, selecting the right graduate program is crucial. The which nurse practitioner program is easiest guide helps identify programs that balance rigor with support, ideal for professionals juggling work and study.

Mental health is another critical area closely tied to immunological research. Programs like the top online PMHNP programs emphasize clinical placements, ensuring hands-on experience in psychiatric mental health nursing.

For budget-conscious students, the cheapest online PMHNP programs offer quality education without the high costs, making advanced nursing degrees more accessible. Together, these options provide diverse pathways aligned with immunology-related careers.

Best Scientists Citing Jacquelyn A. Hank

Trending Scientists